AI at the Bottleneck: The FDA's Blueprint for Smarter Early-Phase Trials

Maya: The FDA is finally asking a question that could reshape drug development: can artificial intelligence safely accelerate the earliest, most uncertain phases of clinical trials?

Sam: Today we are unpacking a Request for Information published by the U.S. Food and Drug Administration. The document is titled AI-Enabled Optimization of Early-Phase Clinical Trials Pilot Program; Request for Information.

Maya: And before we dive in, a quick reminder that our voices are AI-generated, and this is a summary of a public document. But if you are a pharma executive, a trial sponsor, or a digital health developer, this document is essential listening.

Sam: It really is. The FDA is formally stepping into the arena to figure out how AI can be used to streamline early-phase trials. And they are doing this by proposing a pilot program and asking the industry for input on how to build it.

Maya: Exactly. The document starts by laying out the problem very clearly. The agency calls early-phase clinical trials a critical bottleneck in drug development.

Sam: A critical bottleneck. That is strong language for a regulatory agency. What specifically do they say is causing that bottleneck?

Maya: They point to a few specific characteristics. They say these trials are often characterized by high uncertainty, limited patient populations, and inefficient decision-making processes.

Sam: That makes total sense. Early-phase trials are where you are testing a drug in humans for the first time, or trying to find the right dose. You do not have a lot of data yet.

Maya: Right. The document also notes that these trials face long timelines and high resource demands. So, you have a situation where sponsors are spending a massive amount of time and money, but making decisions with very limited information.

Sam: And that is exactly where the FDA thinks AI might be able to help. They list out a whole series of potential benefits. What is at the top of their list?

Maya: The potential of AI, according to the document, includes things like being able to improve patient recruitment and optimize dose escalation. Dose escalation is a huge one in the boardroom. It is how you figure out the maximum safe dose without harming the patient.

Sam: They also mention using AI to enhance safety monitoring and enable adaptive designs. An adaptive design means you can change the trial parameters while the trial is still running, based on the data you are seeing, right?

Maya: Exactly. But the one that really stands out to me from a business and clinical impact perspective is that AI might support earlier Phase 1 to 2 decisions. They specifically mention using AI to enable more informed early go/no-go decisions.

Sam: Go/no-go decisions. Meaning, deciding whether to keep investing in a drug or to kill the program early before you waste more money?

Maya: Yes. The document explicitly calls out a regulatory decision as to whether a Phase 1 study may proceed. If AI can give sponsors and the FDA higher confidence to proceed, or to stop a unsafe trial earlier, that fundamentally changes the risk profile of drug development.

Sam: They also list that AI could improve biomarker assessment, improve biomarker-based patient selection/stratification, and validate endpoints. That is a massive wish list for what AI could achieve.

Maya: It is a massive list, which is exactly why the FDA wants to run a pilot program. They want to see this technology in action, but they want to do it while maintaining FDA's rigorous scientific and regulatory standards and promoting trustworthy AI systems.

Sam: Trustworthy AI systems. That brings us to a really important part of the document. The FDA is not just making up their own rules for what constitutes good AI. They are explicitly pointing to an outside framework.

Maya: Right. The pilot program will be guided by principles aligned with the National Institute of Standards and Technology AI Risk Management Framework. They abbreviate that as the NIST AI RMF.

Sam: What does that framework actually require? The document lists a few key principles.

Maya: The FDA states they support AI use that aligns with NIST principles, specifically that the systems are valid, safe, secure, accountable, explainable, privacy-protective, and fair.

Sam: Valid, safe, secure, accountable, explainable, privacy-protective, and fair. If I am a software vendor building an AI tool for clinical trials, that is my new checklist. I need to prove my tool meets every single one of those words.

Maya: Absolutely. The document also mentions that industry practices already include AI governance, assurance, and risk management frameworks. The FDA aims to enhance the use of AI by industry in line with such practices.

Sam: So, let us talk about how this pilot program is actually going to work. Who is eligible to participate?

Maya: The pilot will recruit sponsors that are currently or will be pursuing early phase clinical trials. These would be through product applications submitted to specific centers: the Center for Drug Evaluation and Research, the Center for Biologics Evaluation and Research, and the Oncology Center of Excellence.

Sam: Okay, so drugs, biologics, and oncology. That covers a huge portion of the pharmaceutical landscape. And who is running the pilot internally at the FDA?

Maya: It will be coordinated by the Deputy Chief Medical Officer within the Office of the Commissioner. That level of oversight shows how seriously they are taking this cross-center initiative.

Sam: Now, the bulk of this document is actually a Request for Information. The FDA is posing a long list of detailed questions to the public, asking for advice on how to design and evaluate this pilot. Let us dig into those questions, because they reveal exactly what the FDA is worried about.

Maya: Let us do it. The questions are broken down into categories. The first category is Pilot Program Design and Implementation. They start by asking about the Scope and Focus.

Sam: Right, they ask: Which trial types or trial issues might benefit most from the application of AI? And they give examples like first-in-human, oncology dose escalation, and rare disease trials.

Maya: Think about why they chose those examples. In rare diseases, you have incredibly limited patient populations. In oncology dose escalation, you are balancing severe toxicity against efficacy. If AI can optimize those specific areas, the impact on human lives and R&D budgets is immediate.

Sam: They also ask if the pilot should target specific therapeutic areas or remain broadly applicable. And they ask if priority should be given to specific AI use cases, like recruitment or safety monitoring.

Maya: Which is a classic resource allocation question. Should the FDA try to boil the ocean, or should they focus this pilot just on safety monitoring to see if the AI can catch adverse events faster than human reviewers?

Sam: Moving on to Participant Selection, they are asking what criteria the FDA should use to select sponsors, trials, or technologies. And they ask how the pilot can ensure representation across organization size, capability, and therapeutic areas.

Maya: That is a nod to the fact that massive pharma companies have huge in-house AI teams, while smaller biotechs might rely entirely on third-party vendors. The FDA wants to make sure this pilot works for the whole ecosystem, not just the giants.

Sam: That leads right into their questions on Collaboration Models. They want to know what partnerships are most effective. They specifically list a sponsor-tech vendor-academic-FDA partnership as an example.

Maya: They also ask a fascinating question here: How can FDA facilitate pre-competitive collaboration and knowledge sharing?

Sam: Pre-competitive collaboration. Meaning, getting competing pharma companies to share their AI methodologies or data before they bring a drug to market. That is notoriously difficult to achieve.

Maya: It is, because everyone wants a proprietary edge. But the FDA knows that to validate these AI models properly, the industry needs shared benchmarks. They even ask what infrastructure is needed, suggesting secure data environments or shared tools.

Sam: Quick note before we carry on. This spot is open for a sponsor. If your company builds or sells AI for healthcare and wants to reach the clinicians, health-system leaders and industry teams who listen to this show, the link to our sponsorship page is in the show notes.

Maya: And now, back to the document.

Sam: Under Operational Structure, they also ask how the pilot can accommodate varying levels of AI maturity across participants. That makes sense, given the different sizes of companies we just talked about.

Maya: They are also looking for input on Timeline and Milestones. They ask what an appropriate duration for the pilot is, and what interim milestones should be included, like enrollment, safety review, or interim analyses.

Sam: And the critical question for any regulator: How should FDA balance rapid insights with rigorous evaluation? That is the eternal tension when dealing with new technology.

Maya: Exactly. And speaking of rigorous evaluation, the second half of their questions focuses entirely on Evaluation Metrics and Success Criteria. This is where the document gets very specific about what proof they need from sponsors.

Sam: They break this down into several areas. The first is Trial Efficiency and Speed. They want to know how improvements in trial efficiency should be measured. They suggest looking at time to initiation, enrollment, or completion.

Maya: They specifically ask what metrics should be used to assess reductions in time from Phase 1 completion to Phase 2 initiation. That gap is often dead time where teams are just crunching data. If AI shrinks that gap, you get to Phase 2 faster.

Sam: They also want to quantify improvements in participant screening, recruitment efficiency, and participant retention. But the next section, Decision Quality, feels like the core of the whole pilot.

Maya: It absolutely is. They ask how the quality and timeliness of go/no-go decisions can be evaluated. And they clarify they mean both FDA regulatory decisions and sponsor-internal decision points.

Sam: And here is a really tricky question they pose: What methods can assess concordance between AI-supported and traditional decision-making?

Maya: Concordance. Basically, if the humans say stop the trial and the AI says keep going, who is right? The FDA needs a way to measure how closely the AI's recommendations match established human expertise before they trust it blindly.

Sam: The next question under decision quality is fascinating. They ask: How should reductions in late-stage trial failures attributable to improved early-phase decisions be measured?

Maya: That is the ultimate goal, right? You use AI in early-phase decisions to pick better drug candidates and better doses, reducing late-stage trial failures. But measuring a failure that you successfully avoided is methodologically very difficult.

Sam: Right, how do you prove the AI saved you from a late-stage failure? You would have to run parallel realities. But the FDA needs industry input on how to design those metrics.

Maya: Then they move to Participant Safety and Data Integrity. They ask what metrics should evaluate the detection and response time for safety signals.

Sam: If AI is monitoring patient vitals and lab results in real-time, it should theoretically detect an adverse event much faster than a human waiting for a weekly report. They want to know how to measure that speed.

Maya: They also ask how the impact of AI on adverse event rates or protocol deviations should be assessed. If the AI is helping optimize the dose correctly, you should theoretically see fewer adverse events.

Sam: Let us talk about AI System Performance, because this is where the tech vendors really need to pay attention. The FDA asks what metrics are most appropriate for evaluating AI model accuracy, robustness, and generalizability.

Maya: Generalizability is crucial. If the AI was trained on data from a large academic medical center, does it still work accurately when deployed at a small community clinic? They specifically ask how performance can be evaluated across different patient populations, trial sites, and therapeutic areas.

Sam: And they ask a highly technical question: How should AI system stability over time be measured, including detection and mitigation of model drift?

Maya: Model drift is what happens when the real-world data starts changing over time, making the AI's original training outdated. In a clinical trial that lasts years, the standard of care might change, or patient demographics might shift. The FDA wants to know how sponsors plan to catch that drift before it ruins the trial data.

Sam: That is a major ongoing maintenance task for any sponsor using these tools. Now, circling back to that NIST framework we discussed earlier, the FDA has a whole section on evaluating Trustworthiness.

Maya: Yes. They ask what evidence should demonstrate that AI systems are valid and reliable in clinical trial contexts. And they ask how safety and risk mitigation associated with AI systems should be evaluated.

Sam: Here is a question that highlights a big industry conflict: What metrics can assess transparency and explainability for different stakeholders, and are there metrics available that would be applicable to both sponsor-developed and proprietary systems?

Maya: The key word there is proprietary. If a tech vendor sells a black-box AI model to a pharma sponsor, the sponsor might not know exactly how it works. But the FDA still needs explainability. Figuring out metrics that work for proprietary systems without forcing vendors to give away their intellectual property is going to be a huge challenge for this pilot.

Sam: They also ask how privacy protections and data governance practices should be evaluated. And critically, they ask: What approaches should be used to assess fairness across demographic and clinical subgroups?

Maya: Fairness is non-negotiable. If an AI tool is optimizing patient recruitment, but it is inadvertently screening out certain demographic groups because of biased training data, that ruins the integrity of the trial. The FDA is making it clear that assessing fairness is part of the validation process.

Sam: To prove all of this works, you have to compare the AI to something. Under Comparative Evaluation, the FDA asks what comparators are most appropriate. They list historical controls, concurrent non-AI trials, and simulation studies.

Maya: Running a concurrent non-AI trial alongside an AI-enabled trial just for comparison would be incredibly expensive. That is why they are asking if historical controls or computer simulations are appropriate substitutes to prove the AI is working safely.

Sam: The last set of questions looks at Qualitative Outcomes. It is not just about the math; it is about the humans using it. They ask how stakeholder trust in AI-enabled trial approaches can be assessed. They list investigators, participants, and regulators as stakeholders.

Maya: If the clinical investigator does not trust the AI's dose recommendation, they are not going to follow it. So, assessing usability and integration into clinical workflows, which the FDA also asks about, is just as important as the algorithmic accuracy.

Sam: They wrap up that section by asking how perceived value, scalability, and operational feasibility should be measured. Basically, does this actually work in the real world at scale?

Maya: Exactly. This entire Request for Information is the FDA acknowledging that AI has massive potential for early-phase trials, but they need the industry to help them write the playbook on how to measure its success and its risks.

Sam: For anyone who wants to submit their input, the document specifies that electronic or written comments must be received by 30 days after the date of publication in the Federal Register.

Maya: And the document is very clear: late, untimely filed comments will not be considered. So, if you are a stakeholder, you have a tight 30-day window to help shape this pilot program.

Sam: You can submit comments electronically via the Federal eRulemaking Portal at regulations.gov. The docket number is FDA-2026-N-4390. Just remember that electronic comments will be posted publicly, so do not include confidential business information there.

Maya: If you do have confidential information you want the FDA to consider, the document gives specific instructions to submit two copies total by mail or hand delivery. One copy includes the confidential information marked clearly, and the second copy must have that information redacted for public viewing.

Sam: This is a pivotal moment. The FDA is actively building the framework that will govern AI in clinical trials for the next decade.

Maya: My memorable takeaway here is the focus on concordance and model drift. The FDA is not just excited about AI's speed; they are deeply focused on ensuring an algorithm's decision aligns with clinical reality, and that it remains stable as real-world data changes over time.

Sam: To recap, the FDA is seeking input on a pilot program to use AI to improve the efficiency and decision-making of early-phase clinical trials. They want industry feedback on pilot design, collaboration, and highly specific evaluation metrics to ensure alignment with trustworthy AI principles.

Maya: You can find a link to the full Request for Information in our show notes. And as always, this podcast is for informational purposes and is not medical advice.